Compare DERM & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | DTIL |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 197.9M |
| IPO Year | 2021 | 2019 |
| Metric | DERM | DTIL |
|---|---|---|
| Price | $6.19 | $6.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $13.75 | ★ $29.40 |
| AVG Volume (30 Days) | 175.0K | ★ 237.8K |
| Earning Date | 11-11-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.72 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $61,858,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $31.55 | N/A |
| Revenue Next Year | $60.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $3.53 |
| 52 Week High | $9.56 | $9.62 |
| Indicator | DERM | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 35.23 |
| Support Level | $5.95 | $6.02 |
| Resistance Level | $6.59 | $7.65 |
| Average True Range (ATR) | 0.41 | 0.39 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 9.18 | 15.89 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).